Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease

a study on Kidney Disease

Summary

Eligibility
for people ages 10-65 (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around

Description

Summary

The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.

Official Title

A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Adult and Pediatric Subjects With APOL1-mediated Proteinuric Kidney Disease

Keywords

Proteinuric Kidney Disease, Kidney Diseases, VX-147

Eligibility

You can join if…

Open to people ages 10-65

You CAN'T join if...

Other protocol defined Inclusion/Exclusion criteria apply.

Locations

  • UCSF School of Medicine accepting new patients
    San Francisco California 94143 United States
  • The Medical Research Group, Inc accepting new patients
    Fresno California 93720 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Vertex Pharmaceuticals Incorporated
ID
NCT05312879
Phase
Phase 2/3 Kidney Disease Research Study
Study Type
Interventional
Participants
Expecting 466 study participants
Last Updated
Contact us about this trial